Stock comparison
Integra LifeSciences
Eli Lilly
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
IART
Integra LifeSciences
Market cap
$1.17B
Sector
Healthcare
LLY
Eli Lilly
Market cap
$1T
Sector
Healthcare
Overall winner
Eli Lilly LLY
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | IART | LLY | Winner |
|---|---|---|---|
| Warren Buffett | 26F | 72B | LLY |
| Benjamin Graham | 40D | 86A | LLY |
| Philip Fisher | 23F | 86A | LLY |
| Peter Lynch | 21F | 74B | LLY |
| Joel Greenblatt | 40D | 78C | LLY |
| Charlie Munger | 22F | 85A | LLY |
| Terry Smith | 15F | 77C | LLY |
Side-by-side metrics
| Metric | IART | LLY |
|---|---|---|
| Market cap | $1.17B | $1T |
| P/E (TTM) | - | 36.6x |
| EV/EBIT | 42.6x | 34.1x |
| ROIC (TTM) | 3.49% | 32.06% |
| Gross margin | 53.21% | 83.51% |
| Net margin | -30.15% | 34.98% |
| Revenue CAGR 5y | 1.47% | 23.17% |
| EPS CAGR 5y | - | 40.81% |
| Debt / Equity | 2.0x | 1.4x |
| Dividend yield | 0.0% | 0.62% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
IART leads on
- P/E (TTM)-vs 36.6x+106%
LLY leads on
- Net margin34.98%vs -30.15%+186%
- Dividend yield0.62%vs 0.0%+100%
- Market cap$1Tvs $1.17B+100%
- Revenue CAGR 5y23.17%vs 1.47%+94%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.